Concepedia

Author

Sabrina Khan

RigshospitaletORCID

Also Known As

S. Khan, Sabrina Khan, Sabrina S Khan, Safiyyah M Khan

37

Publications

1.6K

Citations

12

H-Index

9

Concepts

All Affiliations

RigshospitaletGlostrup HospitalUniversity of CopenhagenChinese Academy of Medical Sciences & Peking Union Medical CollegeEmory University
SK

About

Sabrina Khan is an author at Rigshospitalet specializing in neuropharmacology, neuroscience, and social sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

23

2

Social Sciences

1

1

23

3

Neurology

1

1

23

4

Neuroscience

1

1

23

5

Pharmacology

1

1

23

Sabrina Khan

×

8

Publications

334

Citations

8

H-Index

YearCitations

Meningeal contribution to migraine pain: a magnetic resonance angiography study

Sabrina Khan, Faisal Mohammad Amin, Casper Emil Christensen,

Brain

2018

107

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials

Casper Emil Christensen, Samaira Younis, Marie Deen,

The Journal of Headache and Pain

2018

66

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Aditya Bardia, Komal Jhaveri, Kevin Kalinsky,

Future Oncology

2023

62

Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging

Sabrina Khan, Faisal Mohammad Amin, Frederikke P. Fliedner,

Cephalalgia

2019

35

Reproducibility of migraine-like attacks induced by phosphodiesterase-3-inhibitor cilostazol

Sabrina Khan, Marie Deen, Anders Hougaard,

Cephalalgia

2017

23

Post procedure headache in patients treated for neurovascular arteriovenous malformations and aneurysms using endovascular therapy

Sabrina Khan, Faisal Mohammad Amin, John Hauerberg,

The Journal of Headache and Pain

2016

17

VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial

Barbara Pistilli, Komal Jhaveri, S-A. Im,

Annals of Oncology

2025

13

Abstract GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im,

Cancer Research

2024

11

Page 1